Module

Current Clinical Data on Adjuvant Therapy for HER2-Positive Breast Cancer

Source: Adjuvant HER2-Positive Cancer: Integrating Prognostic Tools and Clinical Advances to Optimize Treatment

Current Clinical Data on Adjuvant Therapy for HER2-Positive Breast Cancer

Faculty:

Nicholas J. Robert, MD

CME CREDIT INFORMATION

Release Date: 11/27/07

Expiration Date: 11/26/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Explain the significance of HER2 in breast cancer
Recall current recommendations for establishing HER2 status
Discuss results of adjuvant studies in HER2-positive breast cancer
Describe the safety profile of HER2-targeting agents

Topics covered include:

Introduction
Biology of HER2 Receptor Tyrosine Kinase
Testing for HER2
Clinical Studies of Trastuzumab in Metastatic Breast Cancer
Adjuvant Trastuzumab Clinical Studies
Trastuzumab Cardiotoxicity
Strategies for Individual Patient Management
Future Directions
Treatment Options After Progression on Trastuzumab
Conclusion

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.